Epigenetics Market - Regional
Analysis
On the basis of geography, global
Epigenetics
Market is segmented into North America, Latin America, Europe, Middle East,
Asia Pacific, and Africa. North America epigenetics market is expected to hold
dominant position in the global market, owing to increasing funding for
research and development activities by government. Furthermore, Asia Pacific
epigenetics market is expected to be fastest growing region owing to high
incidence of cancer. For instance, according to article in Japanese Journal of
Clinical Oncology in 2012, more than 70% of total cancer mortality is reported
in Asia Pacific region and it is projected to rise continuously to 16 million
by 2025.
Epigenetics is the structural
changes in chromosomal regions, which signal or perpetuate alteration in gene
expression by turning it on or off. Epigenetic alteration includes DNA
methylation, histone modification, chromatin remodeling, genomic imprinting, X
chromosome inactivation, and non-coding RNA regulation affecting gene
transcription. Epigenetics is applied for the studies of oncology,
developmental biology, drug development, and non-oncological disorders such as
Alzheimer’s disease and respiratory disease. Epigenetics has applications in in
forensic science for paternity testing, distinguishing between identical twins,
identification of tissue origin, and for estimation of postmortem interval.
Increasing application of epigenetics is expected to propel growth of the
epigenetics market.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1772
Epigenetics Market Drivers
Increasing research to study the
epigenetics of the genome (study called epigenomics) is expected to boost
growth of the epigenetics market over the forecast period. Genome-wide
epigenetic studies play an important role in the diagnostics of human diseases.
Moreover, implementation of epigenetics for oncology research is estimated to
propel the growth of epigenetics market. For instance, Constellation
Pharmaceuticals, in April 2018, invested US$ 100 million for development of
cancer epigenetics platform and ongoing ProSTAR and ORIOn-E trials, which are
designed to demonstrate the potential for CPI-1205 and CPI-0610, used for
cancer therapy. Moreover, increasing whole genome sequencing projects such as
Human Genome Project is resulting into increasing adoption of epigenetic-based
products, which in turn is driving growth of the epigenetics market size.
Increasing government initiatives
to enhance epigenetic research is fueling growth of the epigenetics market. For
instance, in 2017, National Institutes of Health (NIH) planned to award 10
grants for supporting social epigenomics research in health disparities. The
National Institute on Minority Health and Health Disparities (NIMHD), a part of
the National Institutes of Health, committed US$ 26.2 million for nine awards
over the term of five year. Moreover, in 2011, epigenetic related research was
awarded US$ 11 million grant by the U.S. National Institute of Environmental
Health Sciences. In same year, European Commission launched US$ 52.1 million
project named BLUEPRINT, which aims to generate 100 reference epigenomes of
healthy and leukaemic cells.
Furthermore, organic and
inorganic growth strategies such as merger, collaboration, acquisition and
product launches by market players of epigenetics market are expected to fuel
growth of the epigenetics market. For instance, in 2012, Epizyme partnered with
Summit, a subsidiary of Celgene to develop personalized therapeutics for
patients with genetically defined cancers by inhibiting histone methyl
transferases (HMTs), an important epigenetic target class. Under this
agreement, Celgene will receive an exclusive license outside the U.S. to some
of Epizyme’s programs for the period of three years and has the right to extend
this option period for one year with additional funding. Moreover, In January
2016, Merck collaborated with the Cancer Research Technology in U.K., to
develop inhibitors of protein arginine methyltransferase 5 (PRMT5).
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/epigenetics-market-1772
Increasing incidence of cancer is
also expected to upsurge epigenetics market in the near future. For instance,
the global cancer prevalence was predicted to be 32.5 million in 2012, by
Cancer Research UK, which is expected to increase by 68% by 2030. Furthermore,
according to National Cancer Institute (NCI), people undiagnosed cancer
patients reached nearly 14.5 million in 2014, and the number is expected to
reach 19 million by 2024. Moreover, increasing prevalence of chronic disease is
expected to boost growth of the epigenetics market. For instance, according to
Center of Disease Control and Prevention (CDC), 2012, about half of the adult
in U.S, which is 117 million, suffers from one or more chronic health
conditions such as heart disease, stroke, cancer, type 2 diabetes, obesity, and
arthritis
Epigenetics Market Restraint
High maintenance and cost of the
instruments such as next generation sequencing or qPCR, implemented for
epigenetic study are expected to be the key factors hindering growth of the
epigenetics market.
Epigenetics Market – Competitor
Epigenetics market is highly
fragmented. Major players operating in market include Illumina Inc., Thermo
Fisher Scientific Inc., Merck Millipore Limited, Bio-Rad Laboratories, Inc.,
Qiagen Inc., Zymo Research Corporation, Diagenode s. a., Enzo Life Sciences,
Inc. and New England Biolabs Inc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1772
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment